NOVO NORDISK PHARMACEUTICALS A/S — Credit Rating and Financial Key Figures

NOVO NORDISK PHARMACEUTICALS A/S (CVR number: 24257924) is a company from GLADSAXE. The company recorded a gross profit of -46 kDKK in 2024. The operating profit was 5538 kDKK, while net earnings were 6918 kDKK. The profitability of the company measured by Return on Assets (ROA) was 10.6 %, which can be considered good and Return on Equity (ROE) was 12.2 %, which can be considered good. The equity ratio, a key indicator for solidity, stood at 38.9 %, a level that can be considered to be low. This means a higher proportion of debt in its capital structure, indicating a greater reliance on borrowed funds. NOVO NORDISK PHARMACEUTICALS A/S's liquidity measured by quick ratio was 0.9 which is at a modest level. Thus, the company's liquid assets are in relative balance with its short-term liabilities, indicating a moderate liquidity position. While it's likely to meet its current obligations, financial flexibility may be constrained, and unexpected costs could pose challenges.